Enliven Therapeutics COO Anish Patel Sells 48,300 Shares for $1,351,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Source: Yahoo Finance
- Executive Sell-off: Enliven Therapeutics COO Anish Patel sold 48,300 shares on January 9, 2026, totaling $1,351,000, which may raise concerns about the company's future outlook among investors.
- Market Reaction: Executive sell-offs are often perceived as negative signals for stock performance, potentially leading to a decline in investor confidence in Enliven Therapeutics and affecting its stock price.
- Shareholder Structure Change: This sell-off could alter the company's shareholder structure, impacting investor trust in corporate governance and management, which may affect the company's financing capabilities and market image.
- Future Outlook: While the sell-off raises concerns, the company's future strategic direction and performance will remain focal points for investors, necessitating close monitoring of upcoming earnings reports and market developments.
Analyst Views on ELVN
Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 40.20 USD with a low forecast of 35.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.160
Low
35.00
Averages
40.20
High
48.00
Current: 26.160
Low
35.00
Averages
40.20
High
48.00
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
